SBIR/STTR Research Award
Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2
Award amount
$2,178,638Program and phase
SBIR · Phase IIAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ENCODIA INC
- Proposal award date
- 2018-09-20
- Contract end date
- 2021-08-31
- UEI
- XQMHALBLACC9
- Solicitation number
- PA18-935
- Topic code
- 100
Research abstract
ABSTRACT
The goal of this proposal is to repurpose technology developed for Next-Gen
Proteomics to develop a highly-scalable digital serotyping technology for infectious
disease analysis, with particular application to influenza and Covid-19. The approach is
broadly applicable and should greatly improve upon cost, sensitivity, usability, and
throughput of population-level serotyping and greatly improve infectious disease
monitoring and surveillance.NARRATIVE
This proposal aims to repurpose and develop technology for user-friendly,
high-throughput digital serotyping analysis of infectious pathogens. By enabling
serotyping and antibody profiling across large populations, better surveillance and
control of infectious pandemics can be achieved.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- HT protein profiling with a Next-Gen Protein Assay (NGPA)
- Design and directed evolution of an 'Edmanase' enzyme for high-throughput peptide sequencing.
- Directed evolution of N-terminal amino acid binding proteins for application to protein sequencing
- Development of Engineered Trypsin for Proteomics Sample Prep.
- Design and directed evolution of an 'Edmanase' enzyme for high-throughput peptide sequencing
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
8 SBIR/STTR records share this UEI (2016–2021). Reported award amounts total $6,255,660. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services